N
N. Stremsdoerfer
Publications - 4
Citations - 844
N. Stremsdoerfer is an academic researcher. The author has contributed to research in topics: Cancer & Antiestrogen. The author has an hindex of 4, co-authored 4 publications receiving 785 citations.
Papers
More filters
Journal ArticleDOI
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
Bruno Chauffert,F. Mornex,Franck Bonnetain,Ph. Rougier,Christophe Mariette,O. Bouche,J.-F. Bosset,Thomas Aparicio,Laurent Mineur,A. Azzedine,Pascal Hammel,J. Butel,N. Stremsdoerfer,Philippe Maingon,Laurent Bedenne +14 more
TL;DR: This intensive induction schedule of CHRT was more toxic and less effective than gemcitabine alone and was confirmed in a per-protocol analysis for patients who received 75% or more of the planned dose of radiotherapy.
Journal ArticleDOI
Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801)
Olivier Bouché,M. Ychou,Pascal Burtin,Laurent Bedenne,Michel Ducreux,G Lebreton,J. Baulieux,Bernard Nordlinger,Claudio Martin,J.F. Seitz,J. M. Tigaud,E Echinard,N. Stremsdoerfer,Chantal Milan,Ph. Rougier +14 more
TL;DR: There was no statistically significant survival benefit with this toxic cisplatin-based adjuvant chemotherapy, but a risk reduction in recurrence was observed.
Journal ArticleDOI
Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402)
M. Doffoel,F. Bonnetain,O. Bouche,D. Vetter,A. Abergel,S. Fratte,Jean-Didier Grangé,N. Stremsdoerfer,A. Blanchi,Jean-Pierre Bronowicki,F.X. Caroli-Bosc,X. Causse,F. Masskouri,Philippe Rougier,Laurent Bedenne +14 more
TL;DR: It is suggested that TACE improves neither the survival nor the quality of life in patients with HCC and cirrhosis.
Journal ArticleDOI
Cancer du pancréas localement évolué non resécable : chimioradiothérapie d’induction suivie de chimiothérapie par gemcitabine contre chimiothérapie exclusive par gemcitabine : résultats définitifs de l’étude de phase III 2000–2001de la FFCD et de la SFRO
M. Barhoumi,F. Mornex,F. Bonnetain,F. Bonnetain,Ph. Rougier,C. Mariette,O. Bouche,J.-F. Bosset,Thomas Aparicio,L. Mineur,A. Azzedine,P. Hammel,J. Butel,N. Stremsdoerfer,P. Maingon,Laurent Bedenne,Laurent Bedenne,Bruno Chauffert,Bruno Chauffert +18 more
TL;DR: Ce schema d’induction intensive par chimioradiotherapie concomitante est plus toxique et moins efficace que la gemcitabine seule.